A multicenter retrospective study of salvage surgery for patients with residual or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy: SURGES study. This is an ASCO ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Patient receiving chemotherapy. Adding toripalimab to standard first-line chemotherapy significantly prolonged survival in patients with advanced esophageal squamous cell carcinoma. The following ...
Trends in preferred place of death for metastatic melanoma patients in the United States from 2015 to 2024: Analysis of CDC WONDER database. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Please provide your email address to receive an email when new articles are posted on . Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS ...
Kidney cancer, computer illustration. Toripalimab plus axitinib can improve progression-free survival, when compared to sunitinib monotherapy, in patients with treatment-naïve, advanced renal cell ...
The application is supported by data from the phase 2 POLARIS-02 and phase 3 JUPITER-02 studies. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...
Notching another deal in its efforts to extend the global reach of toripalimab, Junshi Biosciences Co. Ltd. granted Dr. Reddy’s Laboratories Ltd. rights to develop and commercialize the PD-1 inhibitor ...
The US Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorz, Coherus BioSciences) in combination with cisplatin and gemcitabine for the first-line treatment of adults with ...
A new immunotherapy, toripalimab, has the potential to change practice in the treatment of nasopharyngeal carcinoma (NPC), say experts. The drug is a monoclonal antibody that blocks programmed cell ...
Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results